Company Timeline
-
2010
PersImmune is founded
-
2014
PersImmune initiates blood and marrow collection protocol with UC San Diego for AML patients.
-
2016
MDS project started. IRB submission for collection protocol.
-
2018
PACTN Phase 1 Clinical Trial begins at UC San Diego. 3 patients enrolled; samples collected from 11 other individuals.
-
2019
Worldwide patents awarded for PACTN
Cohort #1 of clinical trial is completed without toxicity. Cohort #2 approved to start.
PACTN Clinical Trial expands to other UC medical centers
One Patient, One Tumor, One Therapy